Aquestive Therapeutics, Inc. (AQST) 2018 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, and welcome to the Aquestive Therapeutics Year-End 2018 Conference Call. (Operator Instructions) As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Ms. Lauren Walrath, Head, Corporate Marketing and Communications. You may begin.

    早安,歡迎參加 Aquestive Therapeutics 2018 年度年終電話會議。(接線員指示) 提醒各位,本通話將被錄音。現在我想介紹今天會議的主持人:企業行銷與傳播主管 Lauren Walrath 女士。您可以開始了。

  • Lauren Walrath

    Lauren Walrath

  • Thank you, operator. Good morning, and welcome to today's call to review Aquestive Therapeutics' results for the year-ended December 31, 2018. On today's call, I am joined by Keith Kendall, Chief Executive Officer; Ken Marshall, Chief Commercial Officer; Dan Barber, Chief Strategy and Development Officer; and John Maxwell, Chief Financial Officer.

    謝謝您,接線員。早安,歡迎參加今天的電話會議,我們將回顧 Aquestive Therapeutics 截至 2018 年 12 月 31 日止年度的業績結果。今天與我一同出席的有:執行長 Keith Kendall;首席商務長 Ken Marshall;首席策略與發展長 Dan Barber;以及財務長 John Maxwell。

  • Keith will begin by providing an overview of business developments and context for what lies ahead. Next, Ken will discuss the progress of our commercial activities and the SYMPAZAN launch. Dan Barber will provide us with a review of clinical and regulatory developments related to Aquestive's proprietary pipeline. And finally, John will review the company's financial results for the fourth quarter and full year-ended December 31, 2018, and discuss guidance for 2019. Following these remarks, we will open the call to your questions.

    Keith 將先就業務發展概況以及未來展望提供背景說明。接著,Ken 將討論我們商業活動的進展以及 SYMPAZAN 的上市推進情況。Dan Barber 將為我們回顧與 Aquestive 自有產品線相關的臨床與法規進展。最後,John 將回顧公司 2018 年第四季及截至 2018 年 12 月 31 日止全年度的財務結果,並討論 2019 年的指引。在上述發言之後,我們將開放提問。

  • Additional members of Aquestive's management team, inclusive of Dr. Gary Slatko, Chief Medical Officer; and Lori Braender, General Counsel, will be on hand for the Q&A. In total, we expect today's call to last approximately 60 minutes.

    此外,Aquestive 管理團隊的其他成員也將出席問答環節,包括首席醫療長 Gary Slatko 醫師,以及總法律顧問 Lori Braender。整體而言,我們預期今天的電話會議約為 60 分鐘。

  • As a reminder, our remarks today correspond with the press release we issued this morning. In addition, a recording and transcript of today's call will be made available on Aquestive Therapeutics website within the Investor Relations section shortly following the conclusion of this call.

    提醒各位,我們今天的發言內容對應於今早發布的新聞稿。此外,今天電話會議的錄音與逐字稿,將在本次通話結束後不久,於 Aquestive Therapeutics 官網的投資人關係專區提供。

  • During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language as outlined in today's press release as well as the risks and uncertainties affecting the company as described in the risk factors section included in the company's Annual Report on Form 10-K to be filed with the SEC on March 14, 2019. As with any pharmaceutical product candidate under development, there are significant risks with respect to the development, regulatory approval and commercialization of new products. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to Aquestive Therapeutics or any person acting on behalf are expressly qualified in their entirety by this cautionary statement. The company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events or otherwise, except as required under applicable law.

    在本次通話中,公司將作出前瞻性陳述。我們提醒各位注意公司在今日新聞稿中所載的「安全港」聲明,以及公司於 2019 年 3 月 14 日向美國證券交易委員會(SEC)提交之 Form 10-K 年度報告中「風險因素」章節所述、影響公司的風險與不確定性。如同任何正在開發中的藥品候選產品,新產品在研發、法規核准與商業化方面均存在重大風險。鑑於上述不確定性,您不應過度依賴這些前瞻性陳述;其內容僅反映作出陳述當日的情況。此後由 Aquestive Therapeutics 或任何代表其行事之人士所作出的所有後續前瞻性陳述,均在其整體範圍內明確受本項警示聲明之限制。除非適用法律另有要求,公司不承擔在本次電話會議日期後更新其前瞻性陳述之義務,不論係因新資訊、未來事件或其他原因。

  • With that, I will now turn the line over to Keith.

    接下來,我將把電話交給 Keith。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Thank you, Lauren, and thank you, everyone, for joining us today for Aquestive Therapeutics first year-end earnings call. Aquestive Therapeutics is a fully integrated specialty pharmaceutical company committed to developing and commercializing differentiated medicines. We are the world leader in developing high-quality medications with Oral Film technology. We apply our proprietary PharmFilm technology along with our expertise and knowhow to solve therapeutic problems and make it possible for patients and caregivers to better interact with the medicines they need. The benefits of medications delivered with PharmFilm technology include consistent and accurate dosing, improvements to absorption and tolerability and ease of administration. With these advancements, we can provide a positive treatment experience and outcomes for patients and caregivers. This value proposition is the basis for our commercial portfolio and late-stage product pipeline, and it continues to guide our efforts to expand our pipeline with new assets that provide a meaningful value proposition to patients, their caregivers and health care providers.

    謝謝你,Lauren,也謝謝各位今天參加 Aquestive Therapeutics 的首次年終財報電話會議。Aquestive Therapeutics 是一家全面整合的專科製藥公司,致力於研發並商業化具差異化的藥品。我們是以口溶膜(Oral Film)技術開發高品質藥物的全球領導者。我們運用自有的 PharmFilm 技術,結合我們的專業與技術知識,解決治療上的問題,讓病患與照護者能更好地使用他們所需的藥物。以 PharmFilm 技術遞送的藥物優點包括:穩定且精準的劑量、吸收與耐受性的改善,以及更便利的給藥方式。透過這些進步,我們能為病患與照護者帶來正向的治療體驗與結果。此一價值主張是我們商業產品組合與後期產品線的基礎,也持續引導我們擴充產品線,納入能為病患、照護者與醫療照護提供者帶來實質價值的新資產。

  • 2018 was an important year in Aquestive's transformation into a commercial stage specialty pharmaceutical company. Over the course of the year, we built and deployed our commercial capabilities to support the launch of SYMPAZAN. This is the company's first proprietary product to receive FDA approval and the beginning of an epilepsy franchise that offers great promise for patients. We held several productive meetings with the FDA in order to inform plans for advancing our late-stage CNS assets, Libervant and Exservan, into the regulatory review process.

    2018 年是 Aquestive 轉型為商業化階段專科製藥公司的重要一年。在這一年中,我們建立並部署商業能力,以支援 SYMPAZAN 的上市。這是公司第一個獲得 FDA 核准的自有產品,也是我們癲癇產品線的起點,對病患而言極具潛力。我們與 FDA 舉行了數次富有成效的會議,以協助制定推進我們後期中樞神經系統(CNS)資產 Libervant 與 Exservan 進入法規審查流程的計畫。

  • We advanced Proof of Concept studies for 2 candidates in our early-stage pipeline. We also strengthened our management team with the addition of Lori Braender, as our General Counsel, and Dr. Gary Slatko, as our Chief Medical Officer. We also added Nancy Lurker, CEO of EyePoint Pharmaceuticals, to our Board of Directors, and named Sandy Costa as Chairman.

    我們推進了早期產品線中兩項候選產品的概念驗證(Proof of Concept)研究。我們也透過延攬 Lori Braender 擔任總法律顧問,以及 Gary Slatko 醫師擔任首席醫療長,強化了管理團隊。我們亦邀請 EyePoint Pharmaceuticals 執行長 Nancy Lurker 加入董事會,並任命 Sandy Costa 為董事長。

  • We executed on our plans for an IPO and are now listed on the NASDAQ exchange.

    我們依計畫完成首次公開募股(IPO),目前已在 NASDAQ 交易所掛牌上市。

  • In addition to these events, we continue to operate a licensed product business that generates significant revenue and cash to help fund our proprietary pipeline development and commercial initiatives. While the licensed products will continue to provide a strong financial base for our operations into the future, the advancements we're making across our proprietary portfolio are what will drive our future success and shareholder value.

    除上述事件外,我們也持續經營授權產品業務,該業務可產生可觀的營收與現金流,以協助資助我們自有產品線的研發與商業化計畫。雖然授權產品未來仍將為我們的營運提供穩健的財務基礎,但我們在自有產品組合各方面所取得的進展,才是推動未來成功與股東價值的關鍵。

  • Following the approval and launch of SYMPAZAN as planned in late 2018, the company sees a series of clinical regulatory and commercial milestones that will contribute to shareholder growth in 2019 and beyond. To realize that value and continue the transformation of the company into an integrated and growing specialty pharmaceutical company, the company will focus in 3 primary areas in 2019.

    在 2018 年底如期完成 SYMPAZAN 的核准與上市後,公司預期 2019 年及其後將迎來一系列臨床、法規與商業里程碑,進而促進股東成長。為實現該價值並持續推動公司轉型為整合且成長中的專科製藥公司,公司在 2019 年將聚焦三大主要領域。

  • First, we're working to build and lever our commercial capabilities to drive success of SYMPAZAN and our epilepsy franchise. The SYMPAZAN launch is off to a good start. We've built a team of over 50 highly-experienced professionals in marketing, advocacy, managed markets, medical and sales roles, who are engaging with prescribers, health care providers and health plans across all 50 states. While it's still too early in the launch to provide forward-looking guidance, we're very encouraged by early data on scripts and shipments and see the launch curve following analogues for several recent successful launches of reformulated products in specialty areas.

    第一,我們正致力於建立並運用我們的商業能力,以推動 SYMPAZAN 與癲癇產品線的成功。SYMPAZAN 的上市進展良好。我們已建立一支超過 50 人、具高度經驗的專業團隊,涵蓋行銷、倡議、管理式市場、醫學與銷售等職能,並在全美 50 州與處方醫師、醫療照護提供者及健康保險計畫進行互動。雖然目前仍處於上市初期,尚無法提供前瞻性指引,但我們對處方量與出貨的早期數據感到非常鼓舞,並看到上市曲線與近期數個在專科領域成功推出之改良配方產品的類似案例相符。

  • Our activity around SYMPAZAN is also important, as it provides us with the opportunity to meet with and engage with epileptologists, trade access and advocacy partners, who will all be key to the success of Libervant once that product is approved.

    我們圍繞 SYMPAZAN 的各項活動同樣重要,因為這讓我們有機會與癲癇專科醫師(epileptologists)、通路准入與倡議合作夥伴會面並互動;一旦 Libervant 獲得核准,這些都將是其成功的關鍵。

  • Given a greater than 90% overlap in prescribing physicians of SYMPAZAN and Libervant, our focus is on building important relationships now and developing meaningful market insights that will inform our plans for Libervant.

    鑑於 SYMPAZAN 與 Libervant 的開立處方醫師重疊度超過 90%,我們目前的重點是建立重要關係,並發展具意義的市場洞察,以作為我們規劃 Libervant 的依據。

  • Our second area of focus for 2019 is advancing key pipeline programs toward clinical and regulatory milestones. We're very excited about Libervant. The crossover study requested by the FDA will be dosing shortly, and we are preparing to commence our rolling NDA submission with the aim to complete that submission in the second half of '19.

    我們 2019 年的第二個重點領域,是推進關鍵產品線計畫,朝向臨床與法規里程碑前進。我們對 Libervant 感到非常振奮。FDA 要求的交叉試驗將很快開始給藥,我們也正準備啟動滾動式 NDA 申請提交,目標是在 2019 年下半年完成該提交。

  • Our epinephrine program is progressing as well. We had a positive meeting with Health Canada in January. Based on that discussion, we'll be commencing a Proof of Concept study with an improved formulation of product in the second quarter.

    我們的腎上腺素計畫也在持續推進。我們於一月與加拿大衛生部(Health Canada)進行了一次正向的會議。根據該次討論,我們將於第二季以改良配方的產品展開概念驗證(Proof of Concept)研究。

  • Finally, the company will focus on refreshing and expanding our proprietary portfolio of development and commercial products. Our team is searching for and evaluating opportunities that meet certain criteria. First, we're looking for assets that fit within our commercial platform in epilepsy and CNS. We're looking for assets in other therapeutic areas that we have the expertise to advance and for which our technology creates a strong value proposition for patients and caregivers. And finally, we're looking for technologies that alone or as a complement to foreign film can improve patient interactions with the medicines they take.

    最後,公司將專注於更新並擴充我們自有的研發與商業化產品組合。我們的團隊正在尋找並評估符合特定條件的機會。首先,我們尋找能契合我們在癲癇與中樞神經系統(CNS)商業平台的資產。我們也在其他治療領域尋找我們具備推進專業能力、且我們的技術能為病患與照護者創造強勁價值主張的資產。最後,我們尋找能單獨使用或作為口溶膜(foreign film)的補充,以改善病患與其所服用藥物互動方式的技術。

  • Through these efforts, we will create new programs that will continue to build on Aquestive's previous success. By focusing on all 3 areas in 2019, we see the potential for several inflection points represented by the achievement of clinical, regulatory and commercial milestones.

    透過這些努力,我們將建立新的計畫,持續延續並擴大Aquestive過去的成功。藉由在2019年聚焦這三大領域,我們看見多個潛在的關鍵轉折點,將由臨床、法規與商業里程碑的達成所體現。

  • I'll now turn the line over to Ken Marshall, who will review the initiatives that are underway to support the launch of SYMPAZAN and our commercial goals. Ken?

    接下來我把電話交給Ken Marshall,他將回顧目前正在進行、用以支持SYMPAZAN上市以及我們商業目標的各項措施。Ken?

  • Ken W. Marshall - Commercial Leader

    Ken W. Marshall - Commercial Leader

  • Thank you, Keith. We're excited to share that the launch of SYMPAZAN, our first proprietary commercial product is going well. But before getting into the details of our performance, I want to take a moment to reflect on the achievements of 2018.

    謝謝你,Keith。我們很高興與各位分享,SYMPAZAN——我們第一個自有商業化產品——的上市進展良好。不過在深入說明我們的表現細節之前,我想先花點時間回顧2018年的成果。

  • As Keith described, 2018 was a year of transformation for Aquestive. To realize our vision of evolving into a specialty pharmaceutical company with end-to-end capabilities for developing and commercializing differentiated medicines, we had to execute on 3 important goals: develop a commercial function, enter the epilepsy market and then launch SYMPAZAN. Our team delivered against all 3 of these goals in 2018.

    如Keith所述,2018年對Aquestive而言是轉型的一年。為了實現我們朝向具備端到端能力、可開發並商業化差異化藥品的專科製藥公司演進之願景,我們必須達成三項重要目標:建立商業職能、進入癲癇市場,並推出SYMPAZAN。我們的團隊在2018年完成了這三項目標。

  • First, with respect to our commercial function, Aquestive has established a robust capability to translate marketing plans into SYMPAZAN prescriptions and fulfillment. We translated our market insights into focused plans and tactics. We hired, trained and deployed our prescriber, managed markets and trade-facing teams. And we built an operations function that aggregates data from multiple primary and secondary sources to inform our decision-making and help us run an efficient manufacturing and distribution system. These competencies now form a critical commercial capability that's been instrumental in the launch of SYMPAZAN and will also be used to drive future product launches, including Libervant.

    首先,就我們的商業職能而言,Aquestive已建立強健的能力,能將行銷計畫轉化為SYMPAZAN處方與配藥履約。我們把市場洞察轉化為聚焦的計畫與戰術。我們招募、訓練並部署了面向開立處方醫師、醫療保險給付(managed markets)以及通路/貿易端的團隊。我們也建立了一個營運職能,彙整多個一手與二手資料來源的數據,以支援決策,並協助我們運行高效率的製造與配送系統。這些能力如今構成關鍵的商業化能力,對SYMPAZAN的上市至關重要,並將用於推動未來的產品上市,包括Libervant。

  • Our second goal last year was to enter the epilepsy market. Our medical teams started several months before launch with outreach to national and regional KOLs. They also presented and published pivotal data in several key meetings. Our managed markets account managers introduced Aquestive, PharmFilm, and finally, the SYMPAZAN value proposition to the top 50 commercial payers in top 20 Medicaid states. Complementing these efforts, Aquestive began engaging key patient advocacy groups as well.

    我們去年第二個目標是進入癲癇市場。我們的醫學團隊在上市前數個月便開始與全國及區域性的關鍵意見領袖(KOL)接觸。他們也在數個重要會議中發表並刊登關鍵性數據。我們的醫療保險給付(managed markets)客戶經理向前50大商業保險支付方、以及前20個Medicaid州的支付方,介紹了Aquestive、PharmFilm,以及最終SYMPAZAN的價值主張。作為上述努力的補充,Aquestive也開始與重要的病患倡議團體互動。

  • As expected, we received FDA approval for SYMPAZAN on November 1 and launched the product in the first week of December. The field teams immediately engaged our target prescribers and have reached the majority over 2x. We're watching the Symphony audits that are now coming in. In the month of December, the audit reported 17 prescriptions. As with most specialty medicines, the audit significantly understates the first months of prescriptions and takes time to tighten. Based on our analysis, this was in the range of 50% for December. In January and February, Symphony reported 62 and 111 prescriptions, respectively. Because the audits don't fully capture the volume moving through specialty pharmacy and long-term care at this stage in the launch, shipments from wholesale to retail provide a more complete view of our product's performance. Shipments, in virtually all cases, indicate a new script has been received in a pharmacy, and therefore, a good indicator physicians -- and that physicians are interested in the product.

    如預期,我們於11月1日獲得FDA對SYMPAZAN的核准,並在12月第一週推出產品。外勤團隊立即與我們的目標開立處方醫師接觸,且已對其中多數進行超過2次的拜訪觸達。我們正在關注目前陸續回收的Symphony稽核數據。在12月,稽核報告顯示有17張處方。如同多數專科藥品,稽核在上市初期的前幾個月會顯著低估處方量,且需要時間才會更精準。根據我們的分析,12月的低估幅度約在50%左右。在1月與2月,Symphony分別回報62張與111張處方。由於在上市此階段,稽核尚未能完整捕捉經由專科藥局與長期照護通路流動的量,因此由批發到零售的出貨量能更完整反映我們產品的表現。在幾乎所有情況下,出貨都表示藥局已收到新的處方,因此也是醫師——以及醫師對產品有興趣——的良好指標。

  • We received shipment date and net of returns daily and are comfortable that we are tracking at or above our early expectations as well as other novel formulations of existing products that have launched in the epilepsy market before us. This data, along with feedback from our field teams, has affirmed several important market insights supporting our plan.

    我們每日取得出貨資料與扣除退貨後的數據,並有信心目前的追蹤表現符合或高於我們的早期預期,也與在我們之前於癲癇市場上市的其他既有產品新劑型相當或更佳。這些數據,加上外勤團隊的回饋,已確認了數項支持我們計畫的重要市場洞察。

  • First, any change in a treatment plan for patients with LGS are done thoughtfully and slowly because of the fragile nature of these patients. A recent example of that is the transition from branded ONFI to generic clobazam. 17 weeks after the entrance of generics, a full 30% of the market remains branded. This is an extremely slow erosion curve, but consistent with the conservative way a change is introduced into this market.

    第一,對LGS病患的治療計畫做任何變更都會審慎且緩慢地進行,因為這些病患的狀況相當脆弱。近期的一個例子是從品牌藥ONFI轉換到學名藥clobazam。在學名藥進入市場17週後,仍有整整30%的市場維持使用品牌藥。這是一條極為緩慢的流失曲線,但符合在此市場中引入變更時一貫保守的方式。

  • Second, physicians we meet recognize SYMPAZAN's value for the most difficult-to-treat patients that are not well served by liquids and tablets. These are the patients they tend to switch first. Once the change is made, patients routinely stick with that change for long periods of time. This makes our early base of patients extremely important, as we build our brand and our prescriber base. As patients continue to do well and as more clinicians gain experience with the product, we expect adoption to accelerate.

    第二,我們接觸到的醫師認同SYMPAZAN對於最難治療、且液體與錠劑無法良好滿足需求的病患具有價值。這些病患通常也是他們最先進行轉換的族群。一旦完成轉換,病患往往會在很長一段時間內維持該變更。因此,隨著我們建立品牌與開立處方醫師基礎,早期的病患基礎極其重要。隨著病患持續有良好表現、以及更多臨床醫師累積產品使用經驗,我們預期採用速度將加快。

  • Moving forward for the balance of 2019, we'll focus on growing our business by expanding access. Our managed markets' teams continue to meet with payers and are making progress towards our target of 70% of commercial lives under contract by year's end. We currently have multiple significant contracts in legal review. While new-to-market blocks remain and we work to secure broader access, we have a prior authorization and step-edit support program to help process prescriptions. These programs are working well. 90% of PAs are being processed in under 24 hours. We're also offering copay out offsets to patient families with commercial insurance. We're working to ensure Medicaid access with a dedicated effort around the top 20 states. To date, we've seen a very solid response from this market segment.

    展望2019年剩餘期間,我們將透過擴大可近性來專注於業務成長。我們的醫療保險給付(managed markets)團隊持續與支付方會面,並朝向年底前讓70%的商業保險涵蓋人數(commercial lives)納入合約的目標取得進展。目前我們有多份重要合約正在進行法務審查。在新上市產品的限制仍存在、且我們持續爭取更廣泛可近性的同時,我們也提供事前授權(PA)與階梯式用藥編輯(step-edit)支援計畫,以協助處方處理。這些計畫運作良好。90%的PA可在24小時內完成處理。我們也為持有商業保險的病患家庭提供自付額補助抵減。我們正以專案方式聚焦前20個州,努力確保Medicaid的可近性。截至目前,我們在此市場區隔看到非常穩健的回應。

  • We will continue to increase reach and frequency of our sales efforts. The fields now completed an average of 2.5 calls with 4,600 of our prescribers. To date, they have executed more than 85 speaker programs with an average attendance of 9 health care practitioners per meeting. We plan to continue at this pace for the balance of the first half.

    我們將持續提升銷售活動的覆蓋範圍與接觸頻率。外勤團隊目前已對我們的4,600位處方醫師平均完成2.5次拜訪。截至目前,他們已執行超過85場講者活動,每場平均有9位醫療專業人員出席。我們計畫在上半年剩餘期間維持此一節奏。

  • We know that product demonstrations are key to helping physicians understand how easy it is to administer and dose medications on PharmFilm. Demonstrations build interest in SYMPAZAN and future products, like Libervant. For that reason, we're focused on maximizing the number of product demonstrations made through office visits, speaker programs and conferences. Using these channels, we've already shared over 50,000 PharmFilm demonstrations. In addition to physicians, we also continue to build relationship with important advocacy groups, like the LGS Foundation, the Epilepsy Alliance and more than a dozen chapters and affiliates of the epilepsy foundation. We're engaged in the foundations' projects to improve epilepsy education and treatment awareness.

    我們知道,產品示範是協助醫師了解在 PharmFilm 上給藥與劑量調整有多麼容易的關鍵。示範能提升對 SYMPAZAN 以及未來產品(如 Libervant)的興趣。因此,我們專注於透過診所拜訪、講者計畫與會議,將產品示範的次數最大化。透過這些管道,我們已分享超過 50,000 次 PharmFilm 示範。除了醫師之外,我們也持續與重要的倡議團體建立關係,例如 LGS Foundation、Epilepsy Alliance,以及癲癇基金會十多個分會與附屬機構。我們參與這些基金會的專案,以提升癲癇教育與治療認知。

  • And finally, a key platform for success in 2019 is caregiver engagement. We're working to engage caregivers directly through advocacy walks and events and then build product interest and awareness through digital media.

    最後,2019 年成功的一個關鍵平台是照護者互動。我們正透過倡議健走與活動直接與照護者互動,並進一步透過數位媒體建立產品興趣與認知。

  • In closing, we're encouraged by the reception we received and early data. As we continue to ramp our efforts and secure more coverage, prescriptions should continue to increase, broaden our prescriber base and develop deeper relationships with the LGS community.

    總結來說,我們對所獲得的回饋與早期數據感到鼓舞。隨著我們持續加大投入並取得更多給付覆蓋,處方量應會持續增加、擴大開立醫師基礎,並與 LGS 社群建立更深厚的關係。

  • With that, I'll turn it over to Dan for an update on our clinical development program.

    接下來,我把時間交給 Dan,請他更新我們的臨床開發計畫。

  • Daniel Barber - Senior VP and Chief Strategy & Development Officer

    Daniel Barber - Senior VP and Chief Strategy & Development Officer

  • Thank you, Ken. Today, I will focus on recent progress that's been made with respect to the development of 4 investigational product candidates that use our proprietary PharmFilm technology. Libervant, our diazepam buccal film product for the treatment of seizure clusters; Exservan, our riluzole Oral Film product for the treatment of ALS; epinephrine, an asset in our early stage pipeline, which, if successful, would be indicated for the treatment of anaphylaxis; and octreotide, another asset in our early stage pipeline, which could prove the ability to deliver complex molecules on film.

    謝謝你,Ken。今天我將聚焦於近期在 4 項使用我們專有 PharmFilm 技術之研發中產品候選藥物的開發進展。包括:Libervant——我們用於治療癲癇發作群(seizure clusters)的地西泮(diazepam)頰黏膜薄膜產品;Exservan——我們用於治療 ALS 的利魯唑(riluzole)口溶薄膜產品;腎上腺素(epinephrine)——我們早期研發管線中的一項資產,若成功,將適用於治療過敏性休克(anaphylaxis);以及奧曲肽(octreotide)——我們早期研發管線中的另一項資產,可望證明以薄膜遞送複雜分子的能力。

  • I'll begin today by discussing the next propriety product we anticipate adding to our epilepsy franchise, Libervant. Libervant is being developed using the FDA's 505(b)(2) pathway. The reference listed drug is Diastat rectal gel, which is approved for use in patients who suffer from episodes of increased seizure activity, commonly known as seizure clusters. Diazepam, the drug contained in Diastat, is a long-trusted important medication that helps interrupt seizure clusters and has shown to help patients avoid more severe or fatal episodes uncontrolled seizures, known as status epilepticus. Patients, caregivers, school nurses and even physicians express a great deal of discomfort with using a rectal gel. There are nearly 1 million patients who present to hospitals every year for seizure-related rescue treatment. These visits are expensive to the the U.S. health care system, both in resources and dollars.

    我今天先從我們預期將加入癲癇產品組合的下一項專有產品 Libervant 談起。Libervant 係依 FDA 的 505(b)(2) 途徑開發。其參考上市藥品(reference listed drug)為 Diastat 肛門凝膠,該藥已核准用於出現癲癇發作活動增加之病患,通常稱為癲癇發作群。Diastat 所含的藥物地西泮是一種長期被信賴的重要藥物,可協助中斷癲癇發作群,並已證實可幫助病患避免更嚴重或致命的失控癲癇發作事件,即癲癇重積狀態(status epilepticus)。病患、照護者、學校護理師,甚至醫師,對使用肛門凝膠都表達了相當程度的不適。每年約有近 100 萬名病患因癲癇相關的急救治療而前往醫院。這些就醫對美國醫療體系而言成本高昂,無論是資源或金錢。

  • Providing diazepam as a simple-to-administer buccal film medication that can be easily placed inside the cheek would be considered a major advancement and contribute to improve the patient care and management outside the hospital setting--that is the goal with Libervant, to address the needs and preferences of clinicians and patients, especially for the undertreated adult patient population.

    若能將地西泮以易於給藥的頰黏膜薄膜形式提供,只需輕鬆置於臉頰內側,即可被視為一項重大進展,並有助於改善院外情境下的病患照護與管理——這正是 Libervant 的目標:滿足臨床醫師與病患的需求與偏好,特別是對於目前治療不足的成人病患族群。

  • We are in the last stages of development for Libervant. In mid-December, we completed a pre-NDA meeting with the FDA. As a reminder, the 2 main discussion points in our pre-NDA meeting with the FDA last December were: one, a review of our pharmacokinetic or PK data to-date, including our population PK modeling; and two, our review of our safety data. We also discussed the potential for beginning the filing process with the FDA. This is commonly referred to as a rolling submission. We were very encouraged by the feedback we received from the FDA, and we believe that they recognize the need for making new solutions available for patient use.

    我們正處於 Libervant 開發的最後階段。在 12 月中旬,我們完成了與 FDA 的 NDA 送件前(pre-NDA)會議。提醒一下,去年 12 月與 FDA 的 pre-NDA 會議中,兩個主要討論重點為:第一,檢視我們迄今的藥物動力學(PK)數據,包括族群 PK 建模;第二,檢視我們的安全性數據。我們也討論了開始向 FDA 啟動送件流程的可能性。這通常稱為分段送件(rolling submission)。我們對 FDA 的回饋感到非常鼓舞,並相信他們認同需要讓病患可使用新的解決方案。

  • We received our official meeting minutes from the FDA in mid-January. There were no surprises in the meeting minutes, and they were reflective of our understanding of the FDA's views coming out of the pre-NDA meeting. As we communicated in December, the FDA asked us to provide bridging PK data comparing Libervant to Diastat in patients, who are currently on antiepileptic medication or AEDs. As we previously communicated, we were prepared for this outcome and submitted a clinical study synopsis to the FDA immediately following our meeting in December. We received comments back from the FDA at the end of January and submitted our protocol to our Investigational Review Board, or IRB, within days of receiving the FDA's comments. We have since received IRB approval, initiated 2 investigational sites, begun recruiting, and we will begin dosing shortly.

    我們在 1 月中旬收到 FDA 的正式會議紀要。會議紀要沒有任何意外,並反映了我們對 pre-NDA 會議後 FDA 觀點的理解。如同我們在 12 月所溝通的,FDA 要求我們提供橋接 PK 數據,比較 Libervant 與 Diastat 在目前正在使用抗癲癇藥物(AEDs)的病患中的表現。如先前所述,我們已為此結果做好準備,並在 12 月會議後立即向 FDA 提交臨床研究摘要(synopsis)。我們在 1 月底收到 FDA 的意見回覆,並在收到意見後數日內將研究計畫提交至我們的研究審查委員會(IRB)。此後我們已取得 IRB 核准、啟動 2 個試驗中心、開始招募,並將於近期開始給藥。

  • The study design is meant to mimic real-world circumstances as much as possible. In previous PK studies, we required patients to have an enema prior to Diastat dosing and required patients to fast prior to dosing of Diastat and Libervant. In this crossover study, there will be no enemas prior to Diastat dosing and all patients will receive a meal prior to dosing of Diastat and Libervant. These conditions should not only help us finalizing our dosing regimen but should also further highlight the potential advantages of taking Libervant in a real-world setting. The FDA has specifically asked for us to demonstrate that our dosing regimen will have comparable bioavailability to Diastat under conditions of use and this is what our study design is intended to show.

    本研究設計旨在盡可能模擬真實世界情境。在先前的 PK 研究中,我們要求病患在 Diastat 給藥前先灌腸,並要求病患在 Diastat 與 Libervant 給藥前禁食。在這項交叉試驗中,Diastat 給藥前不會進行灌腸,且所有病患在 Diastat 與 Libervant 給藥前都會先進食。這些條件不僅應能協助我們完成劑量方案的最終確認,也應能進一步凸顯在真實世界情境下使用 Libervant 的潛在優勢。FDA 特別要求我們證明,在實際使用條件下,我們的劑量方案將具有與 Diastat 相當的生體可用率,而本研究設計正是為了呈現這一點。

  • Our target enrollment in the study is 24 patients. We believe enrollment will be straightforward since seizure activity is not required during the study. We have multiple sites trained and currently recruiting, and we look forward to giving you an update on recruitment during our Q1 earnings call in May.

    本研究的目標收案數為 24 名病患。我們認為收案將相對順利,因為研究期間不需要出現癲癇發作活動。我們已有多個受訓完成的試驗中心並正在招募中,並期待在 5 月的第一季財報電話會議中向各位更新招募進度。

  • Our long-term safety study continues to progress. We have over 300 uses of Libervant in the study with no reported serious adverse events. We also have a 100% rate of administration to date, meaning that every dose of Libervant removed from a pouch for administration, was successfully used. Recruitment into the study continues to go well. We have successfully enrolled more than 50 adults, and we are confident we will have a robust sample of adult data by the time our NDA submission is completed.

    我們的長期安全性研究持續推進。目前研究中 Libervant 的使用次數已超過 300 次,且未通報任何嚴重不良事件。截至目前我們也維持 100% 的給藥成功率,意即每一劑自包裝袋取出準備給藥的 Libervant 都成功使用。研究收案持續進展良好。我們已成功納入超過 50 名成人,並有信心在 NDA 送件完成時,將擁有充足的成人數據樣本。

  • Now that we have our cross study -- crossover study underway, we will send our official rolling submission plan to the FDA. If the FDA agrees with that plan, then we are prepared to begin the filing process. This is an exciting step forward for our program, and we continue to focus on completing our filing in 2019.

    既然我們的交叉研究——交叉試驗已啟動,我們將把正式的分段送件(rolling submission)計畫提交給 FDA。若 FDA 同意該計畫,我們已準備好開始送件流程。這是我們計畫向前邁進令人振奮的一步,我們仍專注於在 2019 年完成送件。

  • Our third proprietary CNS candidate is Exservan, an oral soluble film formulation of riluzole, for the treatment of ALS, also known as AQST-117. Our filing process with the FDA is underway, and we anticipate having more precise information on the review process in the coming months. We have also seen strong interest from other companies in bringing AQST-117 to markets outside of the U.S. AQST-117 is an important medication option for patients, and we will seek to provide appropriate access to this product to markets outside of the U.S.

    我們第三項專有中樞神經系統(CNS)候選產品是 Exservan,為利魯唑(riluzole)的口溶薄膜劑型,用於治療 ALS,也稱為 AQST-117。我們與 FDA 的送件流程正在進行中,並預期在未來幾個月取得更精確的審查流程資訊。我們也看到其他公司對將 AQST-117 推向美國以外市場展現強烈興趣。AQST-117 對病患而言是一項重要的用藥選擇,我們將尋求在美國以外市場為此產品提供適當的可近性。

  • In addition, we are glad to provide an update on AQST-108, our sublingual film formulation of epinephrine, which is in development for the treatment of anaphylaxis. As a reminder, AQST-108 has the potential to be the first oral treatment for anaphylaxis, a condition which affects up to 5% of the U.S. population and causes millions of visits to hospital emergency departments each year. Patients living with severe allergies or families trying to care for someone with allergies report higher levels of stress, anxiety as well as day-to-day challenges trying to avoid triggers. These patients have to keep a supply of EpiPen in close proximity at all times should an attack come on. Given that many patients fear needles, we see strong interest in and demand for new treatment options.

    此外,我們很高興就 AQST-108 提供最新進展;AQST-108 為我們的舌下薄膜腎上腺素劑型,目前正開發用於治療過敏性休克(anaphylaxis)。提醒各位,AQST-108 有潛力成為首個用於過敏性休克的口服治療方案;此疾病影響多達 5% 的美國人口,且每年造成數百萬次醫院急診就診。患有嚴重過敏的病患,或試圖照護過敏者的家庭,回報其壓力與焦慮程度較高,且在日常生活中為避免誘發因子而面臨各種挑戰。這些病患必須隨時在身邊備有 EpiPen,以防發作突然來襲。鑑於許多病患害怕針頭,我們看到市場對新治療選項有強烈興趣與需求。

  • We have begun to build our therapeutic presence in the allergy space. We have engaged important key opinion leaders in this space at such events as last month's American Academy of Allergy, Asthma & Immunology or AAAAI Annual Conference. Among the insights we gathered is that there are a range of patient needs across the entire spectrum of allergic reactions, up to and including anaphylaxis. Patients currently have few options other than diphenhydramine, commonly called by the brand named Benadryl, for mild allergic reactions or EpiPen for anaphylaxis. We believe patients deserve more and better options for the various grades of allergic reactions that can come on. We will explore these potential options as we progress our AQST-108 program.

    我們已開始在過敏領域建立我們的治療布局。我們在上個月的美國過敏、氣喘與免疫學會(American Academy of Allergy, Asthma & Immunology,簡稱 AAAAI)年會等活動中,與該領域的重要關鍵意見領袖展開交流。我們蒐集到的洞見之一是:在整個過敏反應光譜中,病患需求多元,涵蓋從輕微反應一直到過敏性休克。目前病患除非是輕微過敏反應可用苯海拉明(diphenhydramine,常見品牌名 Benadryl),或過敏性休克使用 EpiPen 之外,選擇不多。我們相信,對於可能發生的不同等級過敏反應,病患值得擁有更多且更好的選項。隨著我們推進 AQST-108 計畫,我們將探索這些潛在選項。

  • We have already demonstrated Proof of Concept for early formulation of the epinephrine product, but set a goal to improve this formulation before proceeding with more clinical trials.

    我們已就腎上腺素產品的早期配方證明概念(Proof of Concept),但在進行更多臨床試驗之前,我們設定目標要先改善該配方。

  • In January, we held a productive meeting with Health Canada to lay out our plans. Following that meeting, we submitted a Clinical Trial Application, or CTA, for their review. As soon as we have feedback on that CTA, we plan to start the next human Proof of Concept study early in the second quarter. Once we have the top line results and analysis from that study, we will be able to assess and report our next steps.

    1 月,我們與加拿大衛生部(Health Canada)舉行了一場富有成效的會議,說明我們的計畫。會後,我們提交了臨床試驗申請(Clinical Trial Application,CTA)供其審查。一旦收到該 CTA 的回饋,我們計畫在第二季初期啟動下一項人體概念驗證研究。在取得該研究的主要結果與分析後,我們將能評估並對外說明後續步驟。

  • Our other complex molecule program is for the development of AQST-305, octreotide. This is an exciting field of study for our organization, given its potential to demonstrate the ability of PharmFilm to deliver protein and peptide drugs. Our team has already succeeded in pushing past accepted boundaries of film products, allowing us to deliver higher drug roads than previously possible. Delivering complex protein and peptide products is an ambitious target with the potential to improve a variety of medications, like octreotide, which can be difficult for some patients to tolerate in its current injectable form. Our team is continuing to fine tune the film formulation for octreotide, and we expect to have more data to share later this year.

    我們另一項複雜分子計畫是開發 AQST-305(奧曲肽,octreotide)。對我們組織而言,這是一個令人振奮的研究領域,因為它有潛力證明 PharmFilm 能夠遞送蛋白質與胜肽藥物。我們的團隊已成功突破薄膜產品的既有界限,使我們能夠遞送比以往更高的藥物負載量。遞送複雜的蛋白質與胜肽產品是一項具雄心的目標,並有潛力改善多種藥物;例如奧曲肽在目前的注射劑型下,部分病患可能較難耐受。我們的團隊持續微調奧曲肽的薄膜配方,並預期在今年稍晚分享更多數據。

  • With that, I will now turn the line over to John.

    接下來,我把電話交給 John。

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • Thank you, Dan. Good morning, everyone. I will start by summarizing the financial results for the fourth quarter and the full year of 2018, and then I will walk you through our outlook for 2019. To remind you, I will be discussing some non-GAAP financial measures this morning. A description of these measures, along with a reconciliation to GAAP, can be found in the news release we issued this morning. I also wanted to point out that we will be filing our audited results on Form 10-K with the SEC later today.

    謝謝你,Dan。各位早安。我將先總結 2018 年第四季與全年財務結果,接著帶各位了解我們對 2019 年的展望。提醒各位,今天上午我會討論一些非 GAAP 財務衡量指標。這些指標的說明,以及與 GAAP 的調節表,可見於我們今早發布的新聞稿。我也想指出,我們將於今天稍晚向美國證券交易委員會(SEC)提交經審計的 Form 10-K 年報。

  • We produced revenues of $67.4 million in 2018, mostly from our licensed products, and we used approximately $3.4 million of cash during the fourth quarter of 2018 and ended the year with a cash position of over $60 million. The fourth quarter was our first full quarter after the IPO that included significant prelaunch spending related to SYMPAZAN. Our cash position, combined with expected revenues from licensed products and SYMPAZAN, puts us in a good funding position for 2019 and gives us the ability to continue to launch SYMPAZAN and advance our proprietary development activities throughout the year.

    我們在 2018 年創造營收 6,740 萬美元,主要來自我們的授權產品;2018 年第四季約使用 340 萬美元現金,並以超過 6,000 萬美元的現金部位結束年度。第四季是我們 IPO 之後的第一個完整季度,其中包含與 SYMPAZAN 上市前相關的重大前期投入支出。我們的現金部位,加上來自授權產品與 SYMPAZAN 的預期營收,使我們在 2019 年具備良好的資金狀況,並讓我們有能力在全年持續推進 SYMPAZAN 的上市工作及自有研發活動。

  • Turning to a quick review of the fourth quarter. We reported total revenue of $16.8 million. This included manufacturing revenue of $8.1 million with 67 million doses shipped; licenses and royalties of $7.3 million; codevelopment and research fees of $1.2 million; and SYMPAZAN net sales of $228,000 in December 2018, the first full month of the launch.

    接著快速回顧第四季。我們報告的總營收為 1,680 萬美元。其中包括:製造營收 810 萬美元,出貨 6,700 萬劑;授權與權利金 730 萬美元;共同開發與研究費用 120 萬美元;以及 2018 年 12 月 SYMPAZAN 淨銷售額 22.8 萬美元(上市後第一個完整月份)。

  • For the fourth quarter 2018, our gross margin was approximately 71%, while the non-GAAP gross margin was approximately 75%. Total cost and expenses were $29.2 million for the fourth quarter 2018. Excluding noncash items, total expenses were $27 million, including R&D costs of $5.4 million and SG&A costs of $17.4 million. SG&A rose in the fourth quarter 2018 because of the launch of SYMPAZAN and higher public company costs. Net loss for the fourth quarter 2018 was $13.9 million or about $0.56 loss per share. Adjusted EBITDA was a loss of $10.2 million in the fourth quarter compared to an adjusted EBITDA loss of $6.3 million in the fourth quarter of 2017.

    2018 年第四季,我們的毛利率約為 71%,而非 GAAP 毛利率約為 75%。2018 年第四季總成本與費用為 2,920 萬美元。扣除非現金項目後,總費用為 2,700 萬美元,其中包含研發(R&D)費用 540 萬美元與銷售、一般及行政(SG&A)費用 1,740 萬美元。2018 年第四季 SG&A 上升,係因 SYMPAZAN 上市以及上市公司成本增加所致。2018 年第四季淨損為 1,390 萬美元,或每股約虧損 0.56 美元。第四季調整後 EBITDA 虧損 1,020 萬美元,相較於 2017 年第四季調整後 EBITDA 虧損 630 萬美元。

  • As I mentioned earlier, total revenue for the full year 2018 was $67.4 million. The full year number included $37.3 million of manufacturing revenue, $24.7 million of licenses and royalties, $5.2 million of codevelopment and research fees and SYMPAZAN net sales. Our license fees were primarily related to Suboxone and Sunovion's apomorphine product. As a reminder, these license fees tend to be chunky and fluctuate from period-to-period. Full year 2018 manufacturing revenue declined approximately 2%, after backing out the early 2017 onetime fee collected related to Suboxone manufacturing exclusivity. Manufacturing and shipped product doses were the drivers of this revenue with 313 million shipped in the full year 2018 compared to 323 million shipped in 2017.

    如我先前提到,2018 年全年總營收為 6,740 萬美元。全年數字包括:製造營收 3,730 萬美元、授權與權利金 2,470 萬美元、共同開發與研究費用 520 萬美元,以及 SYMPAZAN 淨銷售額。我們的授權費主要與 Suboxone 以及 Sunovion 的阿朴嗎啡(apomorphine)產品相關。提醒各位,這些授權費通常呈現不規則的大額入帳,並會隨期間而波動。在扣除 2017 年初與 Suboxone 製造獨家權相關的一次性費用後,2018 年全年製造營收約下降 2%。製造量與出貨劑量是該營收的主要驅動因素;2018 年全年出貨 3.13 億劑,相較 2017 年出貨 3.23 億劑。

  • Leading up to the fourth quarter, volume was up 5% to 6% year-over-year. However, during the fourth quarter, in advance of the various legal decisions around the potential at-risk market entrants of generic competitive products, Indivior began to manage its product supply chain, which led to the full year decline.

    在進入第四季之前,出貨量年增約 5% 至 6%。然而,在第四季期間,因應關於學名藥競品可能以「承擔風險」方式進入市場的各項法律裁決之前,Indivior 開始管理其產品供應鏈,導致全年出貨下滑。

  • Our gross margin on total revenue for the full year 2018 was 69%. Non-GAAP gross margin, after backing out noncash equity compensation and depreciation, was 73% in 2018 compared to 70% in 2017.

    2018 年全年我們在總營收上的毛利率為 69%。非 GAAP 毛利率在扣除非現金股權薪酬與折舊後,2018 年為 73%,相較 2017 年為 70%。

  • Total costs and expenses were $116.4 million for the full year 2018. As a reminder, the 2018 expenses included $27.3 million of onetime charges related to the termination of a pre-IPO equity compensation program. Excluding noncash items in both periods, 2018 expenses rose to $83.1 million from $63.1 million in 2017. The largest driver of this increase was an increase of approximately $12 million of investments in our commercial platform and the launch of SYMPAZAN. In addition, there was an increased investment in public company costs, such as legal, finance and insurance. R&D costs were down modestly due to the timing of clinical development programs.

    2018 全年總成本與費用為 1.164 億美元。提醒一下,2018 年費用包含 2,730 萬美元的一次性費用,與終止 IPO 前股權薪酬計畫相關。在兩個期間皆排除非現金項目後,2018 年費用由 2017 年的 6,310 萬美元上升至 8,310 萬美元。此增幅的最大驅動因素為我們在商業化平台的投資增加約 1,200 萬美元,以及 SYMPAZAN 的上市。此外,上市公司成本(例如法律、財務與保險)投資亦有所增加。研發(R&D)成本因臨床開發計畫時程因素而小幅下降。

  • Net interest costs were down year-over-year at $7.2 million, despite rising interest rates because of higher interest income as a result of our increased cash position in 2018. Other expense of $5.3 million for the full year 2018, related to the valuation of Perceptive's warrants to purchase common stock which were exercised at the IPO.

    儘管利率上升,淨利息成本年比年下降至 720 萬美元,原因是 2018 年現金部位增加帶來較高的利息收入。2018 全年其他費用為 530 萬美元,與 Perceptive 認股權證(用以購買普通股)的估值相關,該等認股權證已於 IPO 時行使。

  • For the full year 2018, the company reported a net loss of $61.4 million or $2.96 loss per share compared to around $9 million in 2017. The increase was driven by onetime equity compensation expenses related to the IPO, increased commercialization cost and increased public company cost. Adjusted EBITDA was a loss of $15.6 million for the full year 2018 compared to positive adjusted EBITDA of $3.8 million for the full year 2017.

    2018 全年,公司淨損為 6,140 萬美元,或每股虧損 2.96 美元,相較 2017 年約 900 萬美元。增加主要由 IPO 相關的一次性股權薪酬費用、商業化成本增加以及上市公司成本增加所致。2018 全年調整後 EBITDA 為虧損 1,560 萬美元,相較 2017 全年調整後 EBITDA 為正 380 萬美元。

  • As we work to set our targets for 2019, we consider the impact of the February 2019 launch at risk by Dr. Reddy's Alvogen and Mylan on Suboxone's share of the market. There are 2 primary impacts. First, the license fees owed under the September 2017 agreement with Indivior will be suspended until the litigation is completed or the parties settle. This suspension of payments results in a direct year-over-year reduction in this revenue category of approximately $16 million to $17 million. Second, as a reminder, our manufacturing revenue is volume-dependent and does not depend on the market price of the product of either Sandoz or Indivior. As we look forward, the volume that we manufacture likely will adjust downward, as the market settles between branded, authorized generic and at-risk generics. This settling will take time, up to 8 to 12 months. And in the interim, we will produce product to support adjustments to the branded and authorized generic supply chains. Once the market settles, we believe that it is possible that the branded product will hold on to a meaningful share of the Suboxone film market, and the remaining market will be shared among the authorized generic and the other generics who are in the market at risk.

    在我們制定 2019 年目標時,我們考量 2019 年 2 月由 Dr. Reddy's、Alvogen 與 Mylan 以「風險上市」(at risk)方式推出產品,對 Suboxone 市占率的影響。主要有兩項影響。第一,依據 2017 年 9 月與 Indivior 的協議所應支付的授權費,將在訴訟結束或雙方和解前暫停。此付款暫停將使該收入類別年比年直接減少約 1,600 萬至 1,700 萬美元。第二,提醒一下,我們的製造收入取決於出貨量,並不取決於 Sandoz 或 Indivior 產品的市場價格。展望未來,隨著市場在品牌藥、授權學名藥(authorized generic)與風險上市學名藥之間逐步穩定,我們的製造量很可能會向下調整。此市場穩定需要時間,約 8 至 12 個月。在此期間,我們將生產產品以支援品牌藥與授權學名藥供應鏈的調整。一旦市場穩定,我們認為品牌產品仍可能維持 Suboxone 薄膜市場中相當可觀的份額,其餘市場將由授權學名藥與其他以風險上市方式進入市場的學名藥共同分食。

  • Film purchase orders of about 150 million strips for the first 5 months of 2019 of branded and authorized generic film compare favorably to the same period in the prior year and are over 20% higher than the previous 5 sequential months. These orders represent a good starting point for our outlook for 2019, but we are still unsure of the full impact of the at-risk generics in the market and have taken a prudent approach to predicting full year 2019 volume. Meaning, we are assuming the full year will be down from 2018, despite the strong start.

    2019 年前 5 個月品牌與授權學名藥薄膜的採購訂單約 1.5 億條(strips),與前一年同期相比表現良好,且較前 5 個連續月份高出逾 20%。這些訂單為我們 2019 年展望提供了良好的起點,但我們仍不確定市場中風險上市學名藥的全面影響,因此在預測 2019 全年出貨量時採取審慎作法。也就是說,儘管開局強勁,我們仍假設全年將低於 2018 年。

  • We have set a volume guidance range of 190 million to 240 million strips for the full year, and we will closely watch how the market is split among the various participants and keep you updated.

    我們設定全年出貨量指引區間為 1.9 億至 2.4 億條(strips),並將密切觀察市場在各參與者之間的分配情況,並持續向各位更新。

  • The other significant impact on 2019 revenue is the launch of SYMPAZAN. While we are encouraged by the early signals compared to our launch expectations, we also believe it is too early to provide specific guidance on this revenue category. As the launch develops, more data becomes available and aspects, like payers are signed, we may be able to guide later in the year. We will certainly keep you abreast of our progress.

    2019 年收入的另一項重大影響是 SYMPAZAN 的上市。雖然相較我們的上市預期,早期訊號令人鼓舞,但我們也認為現在仍過早就此收入類別提供具體指引。隨著上市進展、更多數據可得,以及例如與支付方(payers)完成簽約等事項逐步到位,我們可能在今年稍晚提供指引。我們一定會讓各位隨時掌握我們的進展。

  • With this backdrop, as we outlined in today's release, we are guiding the total revenues in the range of $33 million to $45 million. This 2019 revenue guidance range includes Suboxone- and Sandoz-authorized generic manufacturing revenue of $23 million to $30 million, based on the volume range previously mentioned. The remaining components of our revenue include licenses and royalties on our various licensee marketed products, codevelopment and research fees from licensees and SYMPAZAN net product sales.

    在此背景下,正如我們在今日新聞稿中所述,我們預估總收入指引區間為 3,300 萬至 4,500 萬美元。此 2019 年收入指引包含 Suboxone 與 Sandoz 授權學名藥的製造收入 2,300 萬至 3,000 萬美元,係基於前述的出貨量區間。其餘收入組成包括:我們各項被授權方上市產品的授權與權利金收入、來自被授權方的共同開發與研究費用,以及 SYMPAZAN 的產品淨銷售額。

  • We expect full year 2019 non-GAAP gross margins of 70% to 72% on total revenue. This is in sync with the full year 2018 non-GAAP gross margin percentages. For 2019, we are guiding to a range of non-GAAP adjusted EBITDA loss of $40 million to $45 million, excluding noncash equity compensation expenses. This assumes that we continue to invest in research and development to continue our current programs and begin work later in the year on new pipeline opportunities that we might add and also to continue to launch SYMPAZAN successfully.

    我們預期 2019 全年非 GAAP 毛利率(以總收入計)為 70% 至 72%。此與 2018 全年非 GAAP 毛利率百分比一致。就 2019 年而言,我們指引非 GAAP 調整後 EBITDA 虧損區間為 4,000 萬至 4,500 萬美元,並排除非現金股權薪酬費用。此假設我們將持續投入研發以推進現有計畫,並於今年稍晚開始投入可能新增的新產品線(pipeline)機會,同時也持續推動 SYMPAZAN 的成功上市。

  • We anticipate full year 2019 cash burn of approximately $45 million to $50 million after considering interest, capital spending and working capital effects but prior to any nondilutive capital transactions. We also plan to explore refinancing of our senior debt facility later in 2019, and we will update the market on nondilutive financing opportunities around apomorphine, after Sunovion announces additional information concerning expected timing of approval of that product.

    在考量利息、資本支出與營運資金影響後,但在任何非稀釋性資本交易之前,我們預期 2019 全年現金消耗(cash burn)約為 4,500 萬至 5,000 萬美元。我們也計畫在 2019 年稍晚探索對我們的優先債務融資安排進行再融資,並將在 Sunovion 公布更多關於 apomorphine 預期核准時程的資訊後,就 apomorphine 相關的非稀釋性融資機會向市場更新。

  • Operator, we will now open the line for questions.

    接線員,我們現在開放提問。

  • Operator

    Operator

  • (Operator Instructions) Our first question comes from Gary Nachman with BMO Capital Markets.

    (接線員指示) 我們的第一個問題來自 BMO Capital Markets 的 Gary Nachman。

  • Gary Jay Nachman - Analyst

    Gary Jay Nachman - Analyst

  • Appreciate all the detail and how you're thinking of guidance, given all the moving parts with Suboxone. But maybe just clarify, what sort of share attention are you assuming for the brand and the AG in order to achieve your guidance? And is the revenue in 2019 likely to be more front-end loaded than backend loaded? And then also just how much do you expect the international component to ramp up over the course of the year? And just remind us how those economics compare with the U.S. economics?

    感謝你們提供所有細節,以及在 Suboxone 有許多變動因素下,你們如何思考指引。不過想請你們釐清一下,為了達成你們的指引,你們對品牌藥與 AG(授權學名藥)的市占假設大概是多少?另外,2019 年的收入是否可能較偏向前期(front-end loaded)而非後期(back-end loaded)?再者,你們預期國際業務的部分在一年當中會增加多少?也請提醒我們,這些經濟效益與美國市場的經濟效益相比如何?

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • Gary, so let me first address your first question. So our 150 million strips that we got front loaded are -- first 5 months of purchase orders are certainly going to drive, what I would call, more normal volume that we've seen in the past. I think as the year unfolds, we'll obviously assess where the market is settling out. For right now, we have -- we had projected a decline which would then imply that we would have a second half decline in revenue in the manufacturing category. Obviously, at the same time, SYMPAZAN is ramping up. While we haven't given guidance on that yet, there will be an offsetting effect with that, and exactly the extent of that is still a little bit unknown. With respect to the international part of the Suboxone business. The filings for other countries are in process, and so I wouldn't expect a significant impact in 2019 in terms of uptick of international business. I think that's a future opportunity for us, but we do still see that as a significant opportunity as we go forward.

    Gary,我先回答你的第一個問題。我們前期已取得的 1.5 億條(strips)——也就是前 5 個月的採購訂單——確實將帶動我所稱的、我們過去所見較為正常的出貨量。我認為隨著年度推進,我們顯然會評估市場最終穩定在何種狀態。就目前而言,我們原先預測會下滑,這意味著我們在製造收入類別上,下半年收入將會下滑。同時,SYMPAZAN 正在放量成長。雖然我們尚未就此提供指引,但它會產生抵銷效果,而抵銷幅度究竟多大目前仍有些不確定。至於 Suboxone 業務的國際部分。其他國家的申請文件正在進行中,因此我不預期 2019 年國際業務會有顯著的上升影響。我認為那是我們未來的機會,但我們仍將其視為往後相當重要的機會。

  • Gary Jay Nachman - Analyst

    Gary Jay Nachman - Analyst

  • Okay. And then maybe a couple for Ken on the SYMPAZAN launch. So talk about your confidence in getting to 70% coverage by the end of the year, I think that's your initial target? And what are the gross to nets? And how do you expect those to trend this year? And then from a marketing standpoint, at what point might you add reps to the SYMPAZAN team in order to start preparing for the Libervant launch potentially next year?

    好的。接著可能有幾個問題想請教 Ken,關於 SYMPAZAN 的上市推進。請談談你們對於在年底前達到 70% 覆蓋率的信心,我想那是你們的初始目標?另外,毛額到淨額(gross-to-net)的情況如何?你們預期今年這個指標會如何變化?最後從行銷角度來看,為了可能在明年為 Libervant 上市做準備,你們會在什麼時點為 SYMPAZAN 團隊增加業務代表(reps)?

  • Ken W. Marshall - Commercial Leader

    Ken W. Marshall - Commercial Leader

  • Yes. Good questions, Gary. We're on track for that year-end 70% of lives covered. We mentioned in the upfront section that we have 3 material contracts and legal reviews. We're making good progress with terms with these major payers. Those will kick out, hopefully, in the next several weeks. We've got term sheets -- we've got term sheets in front of all the major PBMs and the major players. We're engaged with the top 20 Medicaid states, and we've just gotten access at 2 -- in 2 major states. We've seen prescriptions coming through that already. So we're seeing a lot of positive signs and signals. We have our trade team in Florida with all the PBMs this week. So we're comfortable right now trending towards that. As far as the sales team and our expansion, I -- we certainly will have a bigger footprint as we move towards Libervant, as we get more clarity on the regulatory pathway, that's going to dictate our timing. But we would substantially increase our footprint in the field as that asset gets closer.

    是的。好問題,Gary。我們正按計畫朝年底達成 70% 受保人(lives)覆蓋率的目標前進。我們在前面開場部分提到,我們有 3 份重要合約正在進行法律審閱。我們與這些主要付款方(payers)在條款上取得了良好進展。希望在接下來幾週內就能敲定。我們已經把條款清單(term sheets)擺在所有主要 PBM 以及主要參與者面前。我們也正與前 20 大 Medicaid 州積極接洽,並且剛在 2 個主要州取得給付准入。我們已經看到處方在那裡開始進來。所以我們看到很多正面的跡象與訊號。本週我們的通路(trade)團隊在佛羅里達與所有 PBM 會面。因此我們目前對於朝該目標推進的趨勢感到有把握。至於銷售團隊與擴編,我——隨著我們朝 Libervant 推進,且在法規路徑更明朗後,我們肯定會有更大的覆蓋版圖,這將決定我們的時程。但當該資產更接近時,我們會在前線大幅擴大我們的佈局。

  • Gary Jay Nachman - Analyst

    Gary Jay Nachman - Analyst

  • Okay. And I just asked also the gross to nets for SYMPAZAN, like, where those are currently? And how you think those might trend?

    好的。我也想問一下 SYMPAZAN 的毛額到淨額(gross-to-net),目前大概在哪個水準?以及你們認為接下來可能會怎麼走?

  • Ken W. Marshall - Commercial Leader

    Ken W. Marshall - Commercial Leader

  • Yes.

    是的。

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • Yes, Gary. So obviously, the first month, if you look at the December gross to nets, it was high because it's the first month, and we made some judgments about some things where we just really didn't have historical data. As we go forward, we will settle out in the 40% to 50% range over the course of the year. So you'll see that settle up to more of a normal level.

    是的,Gary。很明顯地,第一個月如果你看 12 月的毛額到淨額,它偏高,因為那是第一個月,我們在一些事項上做了判斷,當時確實沒有歷史數據可供參考。往後走,全年來看我們會穩定在 40% 到 50% 的區間。所以你會看到它回到比較正常的水準。

  • Gary Jay Nachman - Analyst

    Gary Jay Nachman - Analyst

  • Okay. And then for Dan, just on Libervant. So it sounds like you could start that rolling submission sometime soon And then have the complete submission in the second half of the year. Could you maybe just narrow the time line for us a little bit? And are we going to see an epinephrine any data anytime soon? Sometime in the next few months? I thought we were expecting something sometime soon.

    好的。接著想請教 Dan,關於 Libervant。聽起來你們可能很快就能開始滾動式送件(rolling submission),然後在下半年完成完整送件。你能否把時程再幫我們縮小一點?另外,我們會在近期看到任何腎上腺素(epinephrine)的數據嗎?在接下來幾個月內?我原本以為我們很快就會看到一些結果。

  • Daniel Barber - Senior VP and Chief Strategy & Development Officer

    Daniel Barber - Senior VP and Chief Strategy & Development Officer

  • Yes, absolutely. Thanks, Gary. In terms of starting the rolling submission, we are ready. So all we've done with the rolling submission is timed it to the start of our crossover study. So all of the things we talked about in December have held true. We've stayed on our time line and the activities we expected to conduct. So we remain right on track for the rolling submission. We -- in terms of the date for full submission, we absolutely see that in 2019, as you know, that is driven by enrollment. So our incredible focus is on how do we maximize our ability to enroll quickly. We think we've done that so far with having 2 sites up and running and 2 more sites, which should come online shortly. So we think we'll progress through the 24 patients quickly. In terms of tightening the timing down, I think at this time, it would be -- I think the best we can give is in 2019. In terms of epinephrine data, yes, you will see epinephrine data as we progress through the year. We anticipate starting the study early in Q2. As you know, this is a fairly quick study to conduct, it's a dose-escalating study where there's a 1-week washout period. It's healthy volunteers. So the cohort of patients is fairly straightforward. So we anticipate sharing that data definitely later in this year.

    是的,當然。謝謝,Gary。就開始滾動式送件而言,我們已經準備好了。我們所做的只是把滾動式送件的時間點,配合到我們交叉試驗(crossover study)的啟動。因此,我們在 12 月談到的所有事項都仍然成立。我們一直按照既定時程,以及我們預期要執行的活動在推進。所以我們仍然完全按計畫進行滾動式送件。至於完整送件的日期,我們確實認為會在 2019 年,如你所知,這取決於受試者招募(enrollment)。因此我們的重點非常集中在:如何最大化我們快速招募的能力。我們認為目前做得不錯,已有 2 個試驗中心啟動運作,另外 2 個中心也應該很快就會上線。因此我們認為能夠很快完成 24 位受試者的進度。至於把時間再收斂一些,我想目前——我認為我們能給的最佳指引就是在 2019 年。關於腎上腺素數據,是的,隨著今年進展你們會看到腎上腺素的數據。我們預期在第二季初開始該研究。如你所知,這是一個相對快速可完成的研究,是劑量遞增研究(dose-escalating study),且有 1 週的洗脫期(washout period)。受試者是健康志願者。所以受試者族群相對單純。因此我們預期會在今年稍晚確實分享該數據。

  • Operator

    Operator

  • Our next question comes from Randall Stanicky with RBC Capital Markets.

    下一個問題來自 RBC Capital Markets 的 Randall Stanicky。

  • Randall S. Stanicky - MD of Global Equity Research and Lead Analyst

    Randall S. Stanicky - MD of Global Equity Research and Lead Analyst

  • Great. I only have a couple of questions. Number one on SYMPAZAN, can you just speak to how much stock education you can do around the film delivery that you think can help make it easier to launch Libervant when that ultimately does launch, which I guess would be next year? That's number one. And two, maybe can you speak to the competitive dynamics, the landscape here for Libervant. How you see that playing out, given that it's going to come to market a little bit later than you initially thought. And then number three, for John, can you just help us with the OpEx cadence for the year, given that there's close some moving parts on the spend side. Should we think of that as more equal weighted quarterly? Or is there any specific weighting for the front or backend, either with R&D or SG&A?

    很好。我只有幾個問題。第一個關於 SYMPAZAN,你能否談談你們能在薄膜劑型(film)給藥方式上做多少市場教育(stock education),你認為這能在 Libervant 最終上市時(我猜是明年)讓上市更容易?這是第一個。第二個,也許你能談談 Libervant 的競爭動態與市場版圖。考量到它上市時間會比你們最初預期稍晚,你們怎麼看這會如何發展?第三個給 John,能否協助我們理解今年營業費用(OpEx)的支出節奏,因為支出端有不少變動因素。我們應該把它視為每季較平均的分布嗎?還是研發(R&D)或銷售、一般及行政(SG&A)在前段或後段會有特定的權重?

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • Go ahead.

    請開始。

  • Daniel Barber - Senior VP and Chief Strategy & Development Officer

    Daniel Barber - Senior VP and Chief Strategy & Development Officer

  • Yes, you let me take those first 2. Okay. Yes, Randall, the demonstration strips are critical. I'm looking at the list of attendees on today's call, I think a number of folks have experienced our platform. That's a pivotal moment and the experience with our product. It really brings home to release the value proposition with SYMPAZAN mucoadhesion; with Libervant, the preferred route of administration and an orally administered rescue therapy. We call that a big time in the field. We got 50,000 demo strips that we've run through already, we're producing more. We use those at every conference. Our field sales team puts one of those on the tongue with SYMPAZAN in every person they walk past in a medical office, from the front desk to the physician, and it's absolutely critical. And it's resonating with our targets. So a key part -- and that translates directly to Libervant. And that's the table for that next discussion when we go into the offices. So fundamental for SYMPAZAN to really set the table nicely for the company. And then from a competitive standpoint, I mean, certainly there are a lot of people focusing on the rescue space; there's no doubt. And that's a significantly unsatisfied segment in the epilepsy space. If you look at the need, you've got probably 1.2 million patients that had -- that had continued to experience seizures. If you look at the amount of labeled medicine used in that population, it would treat a fraction of them. And then you look at the dysfunction of the other strategies, people devolve to slow-acting medicines, compounded medicines. So there's significant amount of dysfunction. We feel strongly that a preferred route of administration will be an oral medicine. We think that some of the folks that are targeting coming in with nasal preparation certainly are better than the rectal. But we're comfortable that when all is said and done, that an oral route of administration in a rescue setting will prove to be the preferred way to go.

    是的,你讓我先講前兩點。好。是的,Randall,示範用的薄片非常關鍵。我在看今天電話會議的與會者名單,我想不少人已經體驗過我們的平台。那是一個關鍵時刻,也是對我們產品的體驗。它確實能讓人切身感受到 SYMPAZAN 黏膜黏附(mucoadhesion)的價值主張;而對 Libervant 而言,則是偏好的給藥途徑,以及口服給藥的急救治療。我們稱那是在第一線的一個重大時刻。我們已經用掉了 50,000 片示範薄片,正在生產更多。我們在每一場會議都會使用這些。我們的外勤銷售團隊在每一家醫療院所,從櫃檯到醫師,遇到的每個人都會把 SYMPAZAN 的薄片放到舌頭上,這絕對至關重要。而且這正與我們的目標客群產生共鳴。所以這是一個關鍵部分——而且這也直接轉化到 Libervant。這也為我們進入診所拜訪時的下一段討論鋪好路。因此,SYMPAZAN 對公司而言是非常基礎、能把桌子擺好的一步。然後從競爭角度來看,我是說,當然有很多人聚焦在急救用藥領域;毫無疑問。而那在癲癇領域是一個明顯未被滿足的區塊。如果你看需求,可能有大約 120 萬名患者仍然——仍然持續經歷癲癇發作。如果你看那個族群實際使用的標示適應症藥物用量,只能治療其中一小部分。再看看其他策略的失靈,人們最後會退回去使用起效慢的藥物、或是院內調劑(compounded)的藥物。所以存在相當程度的失靈與低效率。我們強烈認為,偏好的給藥途徑會是口服藥物。我們認為,有些以鼻用製劑切入的公司,確實比直腸給藥更好。但我們有信心,最終在急救情境下,口服給藥途徑將被證明是最受偏好的選擇。

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • I think, Randall, you had a question also on the cadence of operating expenses in the course of the year?

    我想,Randall,你也有一個關於全年營業費用支出節奏的問題?

  • Randall S. Stanicky - MD of Global Equity Research and Lead Analyst

    Randall S. Stanicky - MD of Global Equity Research and Lead Analyst

  • Yes. How do we think about OpEx spend throughout the year?

    是的。我們該如何看待全年 OpEx 的支出走勢?

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • Yes. So if you look at -- a good way to look that -- obviously, we're not giving specific guidance on the OpEx categories, but if you look at the Q4 numbers, and you look at research and development, which is one component, that was about $5 million. And I think that's probably $4 million or $5 million of a cadence, it's probably reasonable. What you will see is diazepam, obviously, over the next couple of months, is going to have spend around with a crossover study. But over the course of the year, diazepam will come down. We think epinephrine still has been a little bit of a less expensive stage of development. But as we go later in the year, we'll add new products, hopefully, and then we'll begin to spend on some of those. And that's why looking at sort of a $4 million or $5 million cadence is probably reasonable. I think on the SG&A side, if you look at Q4, it was on an adjusted basis about $17 million. That included a lot of launch-related expenses. So that's an above-normal trend as the way I would look at that. And as we go into this year, the trend on SG&A on a quarterly basis will be lower than that number.

    是的。所以如果你看——一個不錯的看法是——很明顯我們不會對 OpEx 各類別提供具體指引,但如果你看第四季的數字,再看研發(research and development)這一塊,它大約是 500 萬美元。我認為大概 400 萬到 500 萬美元的節奏,可能是合理的。你會看到地西泮(diazepam)在接下來幾個月,因為交叉試驗(crossover study)會有一些支出。但在全年過程中,地西泮的支出會下降。我們認為腎上腺素(epinephrine)目前仍處於相對較低成本的開發階段。但隨著我們進入今年後段,我們希望能加入新產品,然後就會開始在其中一些產品上投入支出。這也是為什麼以每季約 400 萬到 500 萬美元的節奏來看,可能是合理的。我想在 SG&A 方面,如果你看第四季,調整後大約是 1,700 萬美元。其中包含了許多與上市(launch)相關的費用。所以我會把那視為高於正常水準的趨勢。而進入今年後,SG&A 的季度趨勢會低於那個數字。

  • Randall S. Stanicky - MD of Global Equity Research and Lead Analyst

    Randall S. Stanicky - MD of Global Equity Research and Lead Analyst

  • No, that's helpful. If I can squeeze one more in, Keith, you talked about business development in the prepared comments. So a 2-parter here. Number one, should we be thinking that you're going to be getting additional deals or focusing on additional deals in 2019? And what type of capacity, given that you're launching one product, pushing another one over the finish line, and pushing a pipeline forward, what type of capacity do you have to execute on additional deals?

    不,這很有幫助。如果我可以再塞一個問題,Keith,你在事先準備的發言中提到業務開發。所以這裡有兩個部分。第一,我們是否應該預期你們在 2019 年會取得更多交易或把重心放在更多交易上?第二,考量你們正在推出一個產品、把另一個推到終點線、並推進研發管線,在這樣的情況下,你們有多大的能力去執行額外的交易?

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Well, thanks, Randall. So we'll always focus on looking for products that complement the CNS platform, whether they are going to be developed from scratch or they are mid-development, and potentially, even already commercial-ready. We will also look for places where our knowledge and technology can create a significant value proposition for patients and how they interact with their medicines. And diazepam, epinephrine are clear examples of how we look at that. We've got an organization that's built to support up to 12 development projects in our pipeline at a time, depending on what stages of development they are.

    好的,謝謝你,Randall。所以我們會一直專注於尋找能補強 CNS 平台的產品,不論是從零開始開發、或是處於中期開發階段,甚至可能已經具備商業化條件。我們也會尋找那些我們的知識與技術能為患者及其用藥互動方式創造顯著價值主張的領域。而地西泮、腎上腺素就是我們如何看待這件事的明確例子。我們的組織架構可同時支援管線中最多約 12 個開發專案,視其所處的開發階段而定。

  • The earlier product is in the development stage, it uses one part of our capacity. The later it gets in its development, it uses a different part of our capacity. When they get to be commercial, our manufacturing capacity has a lot of headroom from where we are right now. We have the ability to quote and package probably 1 billion doses a year in our current form, and we're utilizing just a fraction of that at this point in time. Additional capacity is easy enough to bolt on in a short enough horizon so that we don't ever think we're going to get trapped or caught with volume. And I'd say, the last factor to think about is any of the targets we're talking about are going to be significantly fewer doses per year, although at a significantly higher price than Suboxone is right now. So you're not going to see products consuming 250 million or 300 million doses of our capacity when we bring them on.

    產品越早期處於開發階段,就會使用我們產能的一部分。越接近後期開發,就會使用我們產能的另一部分。當它們進入商業化時,我們的製造產能相較於目前狀態仍有很大的餘裕。以我們目前的配置,我們有能力每年報價並包裝大約 10 億劑量,而目前只使用了其中一小部分。在相當短的時間內就能很容易地加掛額外產能,因此我們不認為會被產量所卡住或受限。我想最後一個要考量的因素是,我們正在談的任何標的,其每年的劑量數都會少得多,儘管其價格會顯著高於目前的 Suboxone。所以當我們導入這些產品時,你不會看到它們消耗我們 2.5 億或 3 億劑量的產能。

  • Operator

    Operator

  • Our next question comes from Liana Moussatos with Wedbush Securities.

    我們的下一個問題來自 Wedbush Securities 的 Liana Moussatos。

  • Vasiliana Vireen Moussatos - MD of Equity Research

    Vasiliana Vireen Moussatos - MD of Equity Research

  • You mentioned beginning the NDA submission process for Exservan. What has been accomplished in that? And what do you have left? And when do you think it will be complete?

    你提到已開始 Exservan 的 NDA 送件流程。目前已完成了哪些工作?還剩下哪些?你認為何時會完成?

  • Daniel Barber - Senior VP and Chief Strategy & Development Officer

    Daniel Barber - Senior VP and Chief Strategy & Development Officer

  • Sure. Thanks, Liana. This is Dan. So as you know, there are several major modules of any NDA submission. The first couple of module is around all of the early work, the preclinical work, the CNC work, all of that stuff. Obviously, we're ready to go. So those we will put into the...

    當然。謝謝你,Liana。我是 Dan。如你所知,任何 NDA 申請都有幾個主要模組。前幾個模組涵蓋所有早期工作、臨床前(preclinical)工作、CMC 工作等等。很明顯,我們已經準備就緒。所以這些我們會放進……

  • Ken W. Marshall - Commercial Leader

    Ken W. Marshall - Commercial Leader

  • I think Liana was asking about Exservan.

    我想 Liana 問的是 Exservan。

  • Daniel Barber - Senior VP and Chief Strategy & Development Officer

    Daniel Barber - Senior VP and Chief Strategy & Development Officer

  • My apologies, Liana, I was giving you of Libervant. You can see where my mind is. Yes, Exservan, we have started the process with the FDA. All of the modules are completed. And we should have some clarity on where that discussion is going in the next couple of months. Since we're talking about Exservan, another interesting angle that we're seeing some interest in is outside of the U.S. on this asset. So we will continue to explore those areas as we go through the year.

    抱歉,Liana,我剛剛在講的是 Libervant。你可以看得出我在想什麼。是的,Exservan,我們已經啟動與 FDA 的流程。所有模組都已完成。而在接下來幾個月內,我們應該會更清楚這項討論的走向。既然談到 Exservan,我們看到另一個有趣的面向是,這項資產在美國以外也開始引起一些興趣。因此,我們會在今年持續推進的同時,繼續探索那些領域。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • To be clear though that we submitted, and we're waiting for acceptance.

    不過要說清楚的是,我們已經提交了,正在等待受理。

  • Daniel Barber - Senior VP and Chief Strategy & Development Officer

    Daniel Barber - Senior VP and Chief Strategy & Development Officer

  • We submitted, and we're waiting for acceptance.

    我們已經提交了,正在等待受理。

  • Operator

    Operator

  • Our next question comes from Jason Butler with JMP Securities.

    下一個問題來自 JMP Securities 的 Jason Butler。

  • Douglas Royal Buchanan - Associate

    Douglas Royal Buchanan - Associate

  • It's Roy in for Jason. A couple of quick ones, I guess. For the SYMPAZAN launch, can you give us any more detail on the early physician and caregiver feedback? Does it look like physicians and caregivers that are trying the drug are going to stick with it? And what proportion of the LGS patients are ideally suited for SYMPAZAN due to difficulty swallowing?

    我是 Roy,代替 Jason 提問。我想有幾個簡短的問題。關於 SYMPAZAN 的上市,你們能否提供更多早期醫師與照護者的回饋細節?看起來嘗試用藥的醫師與照護者會持續使用嗎?另外,因吞嚥困難而特別適合使用 SYMPAZAN 的 LGS 病患比例大約是多少?

  • Ken W. Marshall - Commercial Leader

    Ken W. Marshall - Commercial Leader

  • Yes, I think I can take that. Yes, the early feedback -- and this is qualitative from our sales representatives, as a very positive reception from the physicians, very positive reception from the mid-levels, and by that I mean the nurse practitioners and the physicians' assistants, who are really on the front line and hearing from patients and the challenges they have with swallowing medicines and managing high-volume liquids. So we're very comfortable there. I'll track back to the statement we made in the prepared remarks around shipments. The only reason there is a shipment from our wholesale distribution into a retail setting is because a physician has transmitted an electronic script, and we're seeing volume there that makes us very comfortable that we're on track. So I think that's a very strong surrogate for physician interest, too. If you look at where we're getting used, we certainly are appropriate in that LGS population. We don't have enough patient data at this point to really give you a good answer to that. What I will say is there's about 600,000 prescriptions for clobazam annually. About half of those go into that LGS population. We mentioned the stickiness of this group when they do make a change. They average about 8 refills a year. One thing that I am seeing very early on are prescriptions written for multiple months, it doesn't mean that they're getting filled yet for multiple months, I don't have that. But the qualitative feedbacks are good experiences. I, actually, don't have one negative instance that I could think to share from a physician or an office when someone has come in for their second month.

    好的,我想我可以回答。是的,早期回饋——這是我們業務代表提供的質性回饋——醫師端反應非常正面,中階醫療人員也非常正面;我指的是護理師(NP)與醫師助理(PA),他們其實在第一線,直接聽到病患在吞嚥藥物以及管理大量液體劑型方面的挑戰。所以我們對這部分很有信心。我再回到我們在事先準備的發言中提到的出貨說法。我們的批發通路會出貨到零售端,唯一的原因是醫師已經開立並傳送電子處方;我們看到的量讓我們很有信心,認為進度符合預期。所以我認為這也是醫師興趣的一個很強的替代指標。如果看我們目前的使用情況,確實很適用於 LGS 族群。但目前我們還沒有足夠的病患資料,無法給你一個很好的量化答案。我能說的是,每年大約有 60 萬張 clobazam 的處方。其中大約一半是用在 LGS 族群。我們也提過,這個族群一旦做出更換,用藥黏著度很高。他們平均一年大約會續配 8 次。我很早期就看到的一件事是,有些處方會一次開多個月;這不代表他們已經一次領取多個月的藥,我目前沒有那樣的資料。但質性回饋顯示使用體驗良好。坦白說,我想不到任何一個可以分享的負面案例——無論是醫師或診所——當病患來到第二個月回診時。

  • Douglas Royal Buchanan - Associate

    Douglas Royal Buchanan - Associate

  • Okay. Great. And then just a quick one for John on the revenue guidance. Are there any milestone or other payments that are included in that revenue guidance for 2019?

    好的。很好。接著有個給 John 的快速問題,關於營收指引。你們 2019 年的營收指引中是否包含任何里程碑款或其他款項?

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • Yes. Sure. So we have -- as I mentioned before on the Indivior front, the milestones related to that license agreement will be suspended until the at-risk litigation completes or they settle. But year-to-date, we've collected a little over $4 million of milestones in that area. The apomorphine next milestone is really tied to the approval of that product, so that's not likely to occur until next year. So we've taken that out of our guidance. There will be other royalties, and there could be other milestones of a smaller nature. So we're at $4 million to $5 million right now. And then there'll be some modest increase over the course of the year.

    是的。當然。如我先前提到 Indivior 那邊,與該授權協議相關的里程碑款將暫停,直到「風險自負(at-risk)」訴訟結束或雙方和解。不過截至目前為止,我們在那一塊已收取略高於 400 萬美元的里程碑款。Apomorphine 的下一個里程碑主要與該產品的核准掛鉤,因此不太可能在今年發生,應該要到明年。所以我們已把它從指引中移除。還會有其他權利金,也可能會有規模較小的其他里程碑款。因此目前大約是 400 萬到 500 萬美元。接著在今年剩餘期間會有一些小幅增加。

  • Operator

    Operator

  • Our next question comes from Thomas Flaten with Lake Street Capital Markets.

    下一個問題來自 Lake Street Capital Markets 的 Thomas Flaten。

  • Thomas Flaten - Senior Research Analyst

    Thomas Flaten - Senior Research Analyst

  • A couple for Ken. Do you have any rejection reversal data from the pharmacies? And then in conjunction with that, what are the limitations around the copay card in terms of max savings or number of refills? And then my last question for John, you had mentioned earlier that you might -- you would probably have cash to get you cash flow positive following Libervant launch. Is that still the case, do you think?

    有幾個問題想問 Ken。你們有從藥局端取得任何「拒付後翻轉(rejection reversal)」的數據嗎?另外,配合這點,共付額卡(copay card)在最高節省金額或可使用的續配次數方面,有哪些限制?最後一個問題給 John,你先前提到 Libervant 上市後,你們可能會有足夠現金支撐到達成現金流轉正。你現在仍然這麼認為嗎?

  • Ken W. Marshall - Commercial Leader

    Ken W. Marshall - Commercial Leader

  • Yes, in fact, I can speak to the copay program that we have -- not copay program, the step-edit prior authorization program, I think, that's what you're asking. We're getting good traction with that. We have that set up and trained in all the offices to cover meds. It's available at all the pharmacies. It's being widely used with our prescriptions, as you would imagine, in this early stage while we're negotiating access. Many of the standard edits in new-to-market blocks sit in place with all these payers that you really need a lot of good support on this front. We watch that pretty closely. If you look at our turnaround, we're getting about 90% of those that are submitted, turned around in 24 hours. Our average is about 7 hours. That actually is up to an industry norm. We're at the industry average right now, which is pretty quick. I've spent a lot of time with our strategic partner looking at blinded examples of how other CNS companies have done, so that's a very good metric that I just gave. We're getting about 50% of those appeals through. And to give people perspective, that again is an industry norm. That's what you would expect to get at some point. If you'd looked at some of the medicines that have come into the CNS space recently from large companies that are in the migraine space, you probably can figure out who those are; it's easier as I can. Their first couple of months, they had a 20% approval rating going through the same processes. So we're very comfortable that we have a program that's being actively used. It's generating industry average pull-through, and we're optimistic that we can push it higher than that. And then your second question was on -- could you repeat your second question, after the note that says maximum refills? Could you...

    是的,事實上我可以談談我們的共付額方案——不是共付額方案,是我想你問的是「階梯式編輯(step-edit)」的事前授權(prior authorization)方案。我們在這方面進展良好。我們已在所有診所完成設置並訓練,來協助處理用藥覆蓋。所有藥局都可以使用。如你所想,在我們仍在協商給付可近性(access)的早期階段,這套方案在我們的處方上被廣泛使用。新上市藥物常見的許多標準編輯與阻擋機制,在所有這些支付方那邊都會存在,因此你確實需要在這方面提供很強的支援。我們非常密切地監控。如果看我們的處理速度,提交的案件大約有 90% 能在 24 小時內完成回覆。我們平均大約 7 小時。這其實符合產業常態。我們目前就在產業平均水準,速度算相當快。我花了很多時間與我們的策略合作夥伴一起,查看其他中樞神經系統(CNS)公司在盲化(blinded)範例下的表現,所以我剛提供的這個指標非常不錯。我們的申訴(appeals)大約有 50% 能通過。為了讓大家有概念,這同樣也是產業常態。這是你在某個階段會預期達到的水準。如果你看近期一些大型公司把藥物帶進 CNS 領域、尤其是偏頭痛領域的產品,你大概猜得到是哪些公司;這點你比我更容易猜。他們在前幾個月走同樣流程時,核准率只有 20%。所以我們對於這個被積極使用的方案非常有信心。它帶來的「通過拉動率(pull-through)」達到產業平均,我們也樂觀認為可以把它推得更高。然後你的第二個問題是——你能否重複一下你第二個問題,在你提到「最高續配次數」之後的那一段?你可以……

  • Thomas Flaten - Senior Research Analyst

    Thomas Flaten - Senior Research Analyst

  • Yes. No, it was just about the copay card, whether. You have a maximum amount or a number of refills and how that looks?

    是的。不,只是關於共付額卡(copay card),也就是是否有最高金額或可補領的次數,以及那會呈現成什麼樣子?

  • Ken W. Marshall - Commercial Leader

    Ken W. Marshall - Commercial Leader

  • Yes. We have a program that offsets everything up to $10. So you pay -- you pay us a little as $10, but we offset those programs. As I mentioned, the goal of those types -- well, I didn't mention it, as you probably know, the goal of those programs is to support the copay offset while you get the prior authorizations through. So we put in a 3-month window to do that. So we'll cover it for the first 3 months. At that point, if a plan hasn't self-compelled to cover that, we would stop buying that now.

    是的。我們有一個方案,可抵減最高至 10 美元以外的所有費用。所以你支付——你付給我們的金額最低只要 10 美元,但其餘部分由我們透過那些方案來抵減。如我提到的,這類方案的目標——嗯,我其實沒提到,但你可能知道,這些方案的目標是在你取得事前授權(prior authorization)期間,支援共付額的抵減。因此我們設定了一個 3 個月的窗口期來做這件事。所以前 3 個月我們會承擔。到那個時間點,如果保險計畫仍未被迫自行承保,我們就會停止現在繼續買單。

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • Okay. Thomas, on the cash flow question. Obviously, we're going to end the year with $10 million to $15 million of cash or somewhere in that range. What that means to us is that we will be looking, as we've said before, at our different capital options. Given the apomorphine delay, and we still don't know the timing on that yet, we made the decision to focus first on the financing -- refinancing of our debt. That comes due in 2020. But we can move in 2019 to refinance. We will explore the options. We think there's potentially additional amount of little capital that we can get out of that. In addition to that, we think that it is -- there will be savings in terms of principal repayment as well, so that's a cash positive. Then when we think about other options in front of us before we get to equity, you've got the apomorphine milestone under the apomorphine deal that we could do. The cost of capital is too high to do it before approval, so we prefer to wait until after approval, but we certainly do have that as an option in front of us. So we'll be looking, to be clear, at different nondilutive options between now and the end of 2019, which we think will then put us in a good position as we go into the launch of Libervant, which is likely to be in 2020.

    好的。Thomas,關於現金流的問題。顯然,我們年底會有 1,000 萬到 1,500 萬美元的現金,或大約在那個範圍。這對我們而言意味著,我們將會如先前所說,檢視不同的資本選項。考量到 apomorphine 的延遲,而且我們目前仍不清楚其時程,我們決定先把重點放在融資——也就是我們債務的再融資上。該債務在 2020 年到期。但我們可以在 2019 年就進行再融資。我們會探索各種選項。我們認為可能可以從中取得一些額外的小額資金。此外,我們也認為在本金償還方面會有節省,因此對現金流是正面的。接著,當我們思考在走到股權融資之前的其他選項時,你還有 apomorphine 交易項下的 apomorphine 里程碑款可以做。在核准前去做的資金成本太高,所以我們傾向等到核准後再做,但這確實是我們面前的一個選項。因此,說清楚一點,我們會在現在到 2019 年底之間,評估不同的非稀釋性選項,我們認為這將使我們在進入 Libervant 的上市推進時處於良好位置,而那很可能會在 2020 年。

  • Operator

    Operator

  • Our next question comes from Ram Selvaraju with H.C. Wainwright.

    我們的下一個問題來自 H.C. Wainwright 的 Ram Selvaraju。

  • Edward Patrick White - MD of Equity Research & Senior Healthcare Analyst

    Edward Patrick White - MD of Equity Research & Senior Healthcare Analyst

  • This is Edward on for Ram. Just a couple of questions at the end here. You were just talking about the debt, and I was wondering how that's going to be amortized over the years? And what the probabilities are of extension past that 2020 maturity date?

    我是 Edward,代 Ram 提問。最後這裡有幾個問題。你剛才在談債務,我想知道這筆債務未來幾年會如何攤還(amortized)?以及延長到 2020 年到期日之後的可能性有多大?

  • John T. Maxwell - Senior VP & CFO

    John T. Maxwell - Senior VP & CFO

  • Yes. We -- the first repayment on the debt, there is a monthly repayment that starts in May. It's about $500,000 a month. And then we get down to $37 million at the end of 2020. We will be looking at our options sort of, hopefully, by midyear. We think our options are actually really good, in terms of some kind of new debt facility. And we'll announce more once we have more information. But right now, we think that market looks good for that.

    是的。我們——這筆債務的第一筆償還是每月償還,從 5 月開始。大約每月 50 萬美元。然後到 2020 年底會降到 3,700 萬美元。我們希望在年中左右就開始檢視我們的選項。我們認為我們的選項其實非常好,例如某種新的債務融資安排。一旦我們有更多資訊就會再公告。但就目前而言,我們認為那個市場看起來不錯。

  • Edward Patrick White - MD of Equity Research & Senior Healthcare Analyst

    Edward Patrick White - MD of Equity Research & Senior Healthcare Analyst

  • Okay. And then just a final one on seasonality. I know for the epinephrine market, it can be fairly seasonalized, especially in the pediatric market as kids go back to school. And I was wondering if that sort of seasonality would affect any of the other pipeline products or SYMPAZAN, in particular?

    好的。最後一個關於季節性的問題。我知道在腎上腺素(epinephrine)市場,季節性可能相當明顯,尤其是在兒科市場,因為孩子返校。我想知道這種季節性是否會影響其他任何研發管線產品,或特別是 SYMPAZAN?

  • Daniel Barber - Senior VP and Chief Strategy & Development Officer

    Daniel Barber - Senior VP and Chief Strategy & Development Officer

  • This is Dan. On epinephrine, yes, the seasonality is something we're aware of and we don't -- we're not concerned about that from a launch perspective. And I'll pass it over to Ken to talk about that from a SYMPAZAN perspective.

    我是 Dan。關於腎上腺素,是的,我們知道有季節性,但從上市的角度來看,我們——我們不擔心。我把問題交給 Ken,請他從 SYMPAZAN 的角度談談。

  • Ken W. Marshall - Commercial Leader

    Ken W. Marshall - Commercial Leader

  • From a Libervant standpoint, you have that same phenomena on school. There would be seizure action plans, so you could theoretically see a little bump there. I wouldn't expect a big bump, and these breakthroughs are idiopathic. They are not going to be triggered by any certain weather pattern or anything really. And if you look at SYMPAZAN, for some reason, you see some bumps sometimes and some monthly buying, but I think it has nothing to do with patient consumption. I think, again, that's idiopathic. I think when a patient goes on, they take their medicine. It's not seasonal.

    從 Libervant 的角度來看,學校也會有同樣的現象。會有癲癇發作行動計畫(seizure action plans),所以理論上你可能會看到一點小幅上升。我不預期會有很大的上升,而且這些突破性發作是特發性的(idiopathic)。它們不會被任何特定的天氣型態或任何因素真正觸發。而如果你看 SYMPAZAN,不知為何,有時會看到一些波動以及某些月份的採購,但我認為那與病患實際用藥消耗無關。我認為同樣地,那也是特發性的。我認為病患一旦開始用藥,就會按時服藥。它不是季節性的。

  • Operator

    Operator

  • Thank you. I'm currently showing no further questions at this time, I'd turn the call back over to Keith Kendall for closing remarks.

    謝謝。我目前顯示此時沒有其他問題,我會把電話交回給 Keith Kendall 作結語。

  • Keith J. Kendall - CEO, President & Director

    Keith J. Kendall - CEO, President & Director

  • Sure. Thank you, operator. Thank you, everyone, for joining today's call. We appreciate your time and the questions. We look forward to catching up with some of you in the coming weeks at the Oppenheimer Health Care Conference and at the H.C. Wainwright Global Life Sciences Conference. We're very excited about the significant progress that our team has made over the past few months, and we look forward to reporting to you and talking to you more on our progress of SYMPAZAN, Libervant and the rest of our activities on our next call in May. Thank you all very much.

    好的。謝謝你,接線員。謝謝各位參加今天的電話會議。我們感謝各位的時間與提問。我們期待在接下來幾週於 Oppenheimer 醫療保健(Health Care)研討會,以及 H.C. Wainwright 全球生命科學研討會與部分各位再交流。我們對團隊在過去幾個月取得的重大進展感到非常振奮,也期待在 5 月的下一次電話會議中向各位報告,並進一步與各位討論我們在 SYMPAZAN、Libervant 以及其他各項活動上的進展。非常感謝各位。

  • Operator

    Operator

  • Ladies and gentlemen, this concludes today's conference. Thank you for your participation. Have a wonderful day.

    各位女士、先生,今天的會議到此結束。感謝各位的參與。祝各位有美好的一天。